Ibrutinib does not prevent kidney fibrosis following acute and chronic injury

Recent studies suggested that ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, developed for the treatment of chronic lymphocytic leukemia, may prevent NLRP3 inflammasome activation in macrophages, IL-1β secretion and subsequent development of inflammation and organ fibrosis. The role of NLRP3 h...

Descripción completa

Detalles Bibliográficos
Autores principales: Belliere, Julie, Casemayou, Audrey, Colliou, Eloïse, El Hachem, Hélène, Kounde, Clément, Piedrafita, Alexis, Feuillet, Guylène, Schanstra, Joost P., Faguer, Stanislas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184891/
https://www.ncbi.nlm.nih.gov/pubmed/34099830
http://dx.doi.org/10.1038/s41598-021-91491-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184891/
https://www.ncbi.nlm.nih.gov/pubmed/34099830
http://dx.doi.org/10.1038/s41598-021-91491-x

Ejemplares similares